Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Your name:	Emil Barner Dalgaard
Manuscript title:	Forståelsesmodel for de nye targeterede sygdomsmodificerende anti-
Manuscript numb	per (if known): UFL-12-23-0760
In the interest of ti	ransparency, we ask you to disclose all relationships/activities/interests listed below that

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Time frame: Since the initial	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
All support for the prese manuscript (e.g., funding provision of study materials, medical writin article processing charge etc.)  No time limit for this item.	nt ⊠ None	

Click TAB in last row to add extra rows

Tim	Time frame: past 36 months			
2	Grants or contracts from	None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None     Non		

4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations,	None     Non	
	speakers bureaus,		
	manuscript writing or educational events		
	educational events		
6	Payment for expert testimony	⊠ None	
	testimony		
7	Comment Comments on the con-		
7	Support for attending meetings and/or travel		
8	Patents planned, issued or	None     Non	
	pending		
9	Participation on a Data Safety Monitoring Board		
	or Advisory Board		
40			
10	Leadership or fiduciary role in other board,	None     Non	
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	□ None	
		Fresenius (100 stk aktier, værdi dd = 16.104 DKK)	Zealand Pharma A/S (100 stk aktier, værdi dd 34.220)
		,	Novo Nordisk B A/S (120 stk aktier, værdi dd 80.124 DKK)
10	Decaded of another cost		,
12	Receipt of equipment, materials, drugs, medical	⊠ None	
	writing, gifts or other		
	services		
12	Other financial or non-	N None	
13	financial interests		
	Tilluliolal littorosts		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.



Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	e: 12. december 2023			
You	r name: Line Uhrneholt			
Mar	Manuscript title: Forståelsesmodel for de nye targeterede sygdomsmodificerende anti-inflammatoriske lægemidler			
Mar	nuscript number (if known			
In the are retained third committed the following the area and the area area area and the area area area area area area area ar	e interest of transparency, elated to the content of yo parties whose interests manitment to transparency arrelationship/activity/interestionship questions apply to ascript only.  Buthor's relationships/activitys to the epidemiology of ypertensive medication, experienced to the content of the epidemiology of the series and the epidemiology of ypertensive medication, experienced to the content of your particles.	we ask you to disclose all ur manuscript. "Related" ay be affected by the control does not necessarily in est, it is preferable that you the author's relationship rities/interests should be go hypertension, you should yen if that medication is not port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.	
011101	items, the time traine for	ansonosar o is the past oo i	nontris.	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Time	e frame: Since the initial plan	ning of the work		
1	All support for the present	None     Non		
	manuscript (e.g., funding, provision of study			
	materials, medical writing,			
	article processing charges,			
	etc.)			
	No time limit for this			
	item.			
			Click TAB in last row to add extra rows	
Time	e frame: past 36 months			
	o mamor past oo months			
2	Grants or contracts from	None     Non		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	None     Non		

4	4 Consulting fees None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None  Janssen	Speaker's fee (October 2021)
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None     Non	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None     Non	
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     ■     None     None	
13	Other financial or non- financial interests	⊠ None	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	<b>e</b> : 12. december 2023		
You	r name: Kristine Jagd Ot	tosen	
Mai	nuscript title:Forstaelsesmoo	del for de nye targeterede sy	gdomsmodificerende anti-inflammatoriske lægemidler
Maı	nuscript number (if known	):	
are ro third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit cent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.  Os/activities/interests as they relate to the current
The a perta antih In ite	nins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
		<del></del>	Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	NZ Na	
2	any entity (if not indicated	⊠ None	
	in item #1 above).		
3	Royalties or licenses	⊠ None	

4	Consulting fees	<b>⊠</b> None	
5	Payment or honoraria for	<b>⊠</b> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>⊠</b> None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or	<b>⊠</b> None	
	pending	110110	
9	Participation on a Data None		
9	Safety Monitoring Board	<b>⊠</b> None	
	or Advisory Board		
10	Leadership or fiduciary	<b>⊠</b> None	
	role in other board, society, committee or		
	advocacy group, paid or		
	unpaid		
L			
11	Stock or stock options	<b>⊠</b> None	
12	Receipt of equipment,	<b>⊠</b> None	
	materials, drugs, medical		
	writing, gifts or other services		
	sei vices		
13	Other financial or non-	<b>⊠</b> None	
	financial interests		

 $oxed{\boxtimes}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date:	11. december 2023		
Your n	Your name: Tue Kragstrup		
Manuscript title: Forståelsesmodel for de nye targeterede sygdomsmodificerende anti-			
Manuscript number (if known): UFL-12-23-0760			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	1	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Kragstrup lab har modtaget støtte indenfor de sidste 5 år fra Gigtforeningen, Axel Muusfeldts Fond, Beckett Fonden, Bjarne Jensens Fond, Danielsens Fond, Hørslev Fonden, Kong Christian den Tiendes Fond, Fonden til Lægevidenskabens Fremme, Direktør Michael Hermann Nielsens Mindelegat, Civilingeniør Frode V. Nyegaard og Hustru's Fond, Oda og Hans Svenningsens Fond.	

			Click TAB in last row to add extra rows
Tim	e frame: past 36 months		
2	Grants or contracts from	None     Non	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None     Non	
	-		
5	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus,	Eli Lilly, UCB, Abbvie, Pfizer	
	manuscript writing or	THZE	
	educational events		
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None     Non	
,	meetings and/or travel	□ None	
8	Patents planned, issued or	□ None	
	pending	Cofounder of spinout	
		company Aptol Pharma (www.aptolpharma.com	
		)	
9	Participation on a Data	■ None	
	Safety Monitoring Board or Advisory Board		
10	-		
10	Leadership or fiduciary role in other board,	☐ <b>None</b> Chair of the eular	
	society, committee or	EMEUNET Committee	
	advocacy group, paid or unpaid	(www.emeunet.eular.or	
	anpaid	g/index.cfm)	
11	Stock or stock options	□ None	

		Novo Nordisk, Zealand, Eli Lilly, Astra Zeneca, Lundbeck
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None     Non

oxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.